2,5-Dichloro-3-nitropyridine

We are 2,5-Dichloro-3-nitropyridine CAS:21427-62-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:2,5-Dichloro-3-nitropyridine
CAS.NO:21427-62-3
Synonyms:2,5-Dichloro-3-nitropyridine
2,5-dichloro-3-nitro-pyridine
2-amino-5-chloro-3-nitrobenzene
3-nitro-2,5-dichloropyridine
2,5-Dichlor-3-nitro-pyridin
2,5-dichloronitropyridine
Molecular Formula:C5H2Cl2N2O2
Molecular Weight:192.98800
 
Physical and Chemical Properties:
Density:1.629
Melting point:39-45ºC
Boiling point:265.3ºC
Flash point:114.2ºC
Index of Refraction:1.603
 
Specification:
Appearance:Yellow crystal
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Applicationd to synthesize 5-Chloro-2,3-difluoropyridine, 5-Chloro-2,3-difluoropyridine is an important intermediate of Clodinafop Propargyl

2,5-Dichloro-3-nitropyridine


Related News: Over the years, large international pharmaceutical companies have gradually focused on the research and development and sales of patented drugs, and have gradually outsourced traditional products. Among them, most of the contractors are pharmaceutical companies in emerging countries.Methyl 3-methylthiopropionate Over the years, large international pharmaceutical companies have gradually focused on the research and development and sales of patented drugs, and have gradually outsourced traditional products. Among them, most of the contractors are pharmaceutical companies in emerging countries.Dibromomethane “Our collaboration with Mankind demonstrates our commitment towards providing novel, innovative treatment options for efficient diabetes management,” Glenmark Pharmaceuticals President, India Formulations, Middle East and Africa Sujesh Vasudevan said.4-fluoro-2-nitro-1-(trifluoromethyl)benzene CAS:182289-81-2 Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).

Related Products
Product Name
2-Chloro-4-bromobenzaldehyde View Details
4-bromobutanoic acid View Details
2-(piperidin-1-yl)ethanol View Details
DI-T-BUTOXYDIACETOXYSILANE manufacturer 2-METHYL-5-HYDROXY PYRIDINE manufacturer 2-Chloro-1-cyclopropyl-2-(2-fluorophenyl)ethanone manufacturer 2,4-Difluorophenyl Isothiocyanate manufacturer 2,2′-Dihydroxy-4,4′-dimethoxybenzophenone-5,5′-disulphonic acid sodium salt manufacturer